Zai Lab Limited announced completion of patient enrollment of its pivotal trial of niraparib (ZL-2306; ZEJULA) in development for second-line maintenance therapy in patients with recurrent, platinum-sensitive ovarian cancer. The Phase 3 trial is evaluating niraparib as a second-line maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer. Recurrent ovarian cancer patients who have responded to a platinum-containing regimen were enrolled in the study and randomized 2:1 to receive either niraparib or placebo once daily. Patients were stratified by gBRCA status. The primary endpoint is progression-free survival. The study enrolled its first patient in September 2017.